Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD

Krystal, John H.; Rosenheck, Robert A.; Cramer, Joyce A.; Vessicchio, Jennifer C.; Jones, Karen; Vertrees, Julia E.; Horney, Rebecca A.; Huang, Grant D.; Stock, Christopher

doi:10.1001/jama.2011.1080

Cited by 205 publications

(140 citation statements)

References 47 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…Anticonvulsants and atypical antipsychotics are also used to treat PTSD. These medications are associated with limited response rates and residual symptoms, particularly in PTSD, and adverse effects may also limit tolerability and adherence [7][8][9][10]. The substantial burden of anxiety-related disorders and the limitations of current treatments place a high priority on developing novel pharmaceutical treatments.…”

Section: Introductionmentioning

confidence: 99%

Cannabidiol as a Potential Treatment for Anxiety Disorders

et al. 2015

View full text Add to dashboard Cite

Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations.

show abstract

Section: Introductionmentioning

confidence: 99%

Cannabidiol as a Potential Treatment for Anxiety Disorders

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Therefore, it may not be surprising that an SRI study in veterans produced negative results. Second-generation antipsychotics [SGAs] are widely used medications for SRI-resistant PTSD symptoms, despite limited evidence supporting this practice" [17]. A research team at the VA Connecticut Healthcare System in West Haven, Connecticut, headed by John H. Krystal, studied the SGA risperidone, which revealed that there was no statistically significant difference after 6 months of treatment between risperidone and placebo in reducing PTSD symptoms.…”

Section: Conventional Methods Of Treatment For Ptsdmentioning

confidence: 99%

Community-Based Wounded Warrior Sustainability Initiative (CBWSI): An integrative medicine strategy for mitigating the effects of PTSD

Sniezek¹

2012

JRRD

View full text Add to dashboard Cite

“…The greatest improvement was seen on intrusive thoughts and hypervigilance symptom subscales. A 6-month randomised double-blind placebocontrolled multicentre study of adjunctive risperidone published after Ahearn et al 's review (Krystal 2011) did not find it to be of significant help in reducing PTSD symptoms.…”

Section: Quetiapinementioning

confidence: 97%

Post-traumatic stress disorder: new directions in pharmacotherapy

Green¹

2013

Adv. psychiatr. treat

View full text Add to dashboard Cite

SummaryAs many as 10% of the population experience post-traumatic stress disorder (PTSD) at some time in their lives. It often runs a severe, chronic and treatment-resistant course. This article reviews the evidence base for typically recommended treatments such as cognitivebehavioural therapy (CBT), eye movement desensitisation and reprocessing and selective serotonin reuptake inhibitors (SSRIs). It tabulates the major randomised controlled trials of SSRIs and trauma-focused CBT and reviews research on novel treatments such as ketamine, MDMA, quetiapine, propranolol and prazosin.

show abstract

Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD

Abstract: clinicaltrials.gov Identifier: NCT00099983.

Cited by 205 publications

References 47 publications

Cannabidiol as a Potential Treatment for Anxiety Disorders

Cannabidiol as a Potential Treatment for Anxiety Disorders

Community-Based Wounded Warrior Sustainability Initiative (CBWSI): An integrative medicine strategy for mitigating the effects of PTSD

Post-traumatic stress disorder: new directions in pharmacotherapy

Contact Info

Product

Resources

About